Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2020.10.045 http://scihub22266oqcxt.onion/10.1016/j.ijid.2020.10.045 33115682!7585732!33115682     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 102 (ä): 303-309 Nephropedia Template TP {{tp|p=33115682|t=2021. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia |pdf=|usr=}}{{33115682}} gab.com Text Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33115682 #FOAvip INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data about who might benefit most from it. METHODS: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation >93%. The primary endpoint was intubation or death after 24 h of its administration. Patients received at least one dose of 400 mg intravenous TCZ from March 8, 2020 to April 20, 2020. RESULTS: A total of 207 patients were studied and 186 analyzed. The mean age was 65 years and 68% were male patients. A coexisting condition was present in 68% of cases. Prognostic factors of death were older age, higher IL-6, d-dimer and high-sensitivity C-reactive protein (HSCRP), lower total lymphocytes, and severe disease that requires additional oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0.001) in those receiving the drug when the oxygen support was high (FiO2 >0.5%). CONCLUSIONS: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs. Twit Text FOAVip Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33115682 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33115682 #FOAvip English Wikipedia <ref>{{Cite pmid|33115682}}</ref> Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia #MMPMID33115682 Gorgolas Hernandez-Mora M; Cabello Ubeda A; Prieto-Perez L; Villar Alvarez F; Alvarez Alvarez B; Rodriguez Nieto MJ; Carrillo Acosta I; Fernandez Ormaechea I; Al-Hayani AWM; Carballosa P; Calpena Martinez S; Ezzine F; Castellanos Gonzalez M; Naya A; Lopez De Las Heras M; Rodriguez Guzman MJ; Cordero Guijarro A; Broncano Lavado A; Macias Valcayo A; Martin Garcia M; Becares Martinez J; Fernandez Roblas R; Piris Pinilla MA; Fortes Alen J; Sanchez Pernaute O; Romero Bueno F; Heili-Frades S; Peces-Barba Romero G Int J Infect Dis 2021[Jan]; 102 (ä): 303-309 PMID33115682show ga INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data about who might benefit most from it. METHODS: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation >93%. The primary endpoint was intubation or death after 24 h of its administration. Patients received at least one dose of 400 mg intravenous TCZ from March 8, 2020 to April 20, 2020. RESULTS: A total of 207 patients were studied and 186 analyzed. The mean age was 65 years and 68% were male patients. A coexisting condition was present in 68% of cases. Prognostic factors of death were older age, higher IL-6, d-dimer and high-sensitivity C-reactive protein (HSCRP), lower total lymphocytes, and severe disease that requires additional oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0.001) in those receiving the drug when the oxygen support was high (FiO2 >0.5%). CONCLUSIONS: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |C-Reactive Protein/immunology[MESH] |COVID-19/immunology/mortality/virology[MESH] |Compassionate Use Trials[MESH] |Critical Care/statistics & numerical data[MESH] |Female[MESH] |Humans[MESH] |Immunologic Factors[MESH] |Interleukin-6/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/drug effects/physiology[MESH]Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia (epmc).pdf DeepDyve Pubget Overpricing